Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
Jun 22 LLY GLP-1 drugs linked to reduced dementia risk: study
Jun 22 LLY ResMed, Philips under pressure as Eli Lilly seeks sleep indication for weight loss drug
Jun 22 PFE The Most Populated Country in the World
Jun 22 PFE 3 No-Brainer Stocks to Buy for Under $100 Right Now
Jun 22 PFE 3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
Jun 21 LLY Lilly weight loss drug tirzepatide meets primary endpoint in sleep apnea study
Jun 21 LLY Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
Jun 21 PFE Sarepta’s Elevidys secures US label expansion for DMD
Jun 21 LLY Eli Lilly’s Weight-Loss Franchise Has Been a Massive Winner Under Dave Ricks
Jun 21 PFE Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Jun 21 LLY Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Jun 21 PFE FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
Jun 21 LLY WHO warns of “harmful” fake Ozempic in circulation in Americas and Europe
Jun 21 LLY Hims & Hers defended at BofA as Lilly fights compounded GLP-1s
Jun 21 LLY Here's How Much a $1000 Investment in Eli Lilly Made 10 Years Ago Would Be Worth Today
Jun 21 LLY Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss
Jun 21 LLY The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
Jun 21 PFE The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
Jun 21 PFE Sarepta Stock Surges on Expanded Approval for Elevidys. What Wall Street Thinks.
Jun 21 LLY AI Stocks Are Soaring on Hope. Why Their Dominance Puts Markets at Peril, and 4 Other Things to Know Today.
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags